Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Stefansson

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 8, 2020
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trialHiddo J L Heerspink, Bergur V Stefansson, Glenn M Chertow, et al.
Advances in Therapy|December 9, 2021
Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled TrialsJuan Jose Garcia Sanchez, Juliette Thompson, David A Scott, et al.
The Lancet. Diabetes & Endocrinology|October 7, 2021
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialHiddo J L Heerspink, Niels Jongs, Glenn M Chertow, et al.
Diabetes, Obesity & Metabolism|January 5, 2022
Quételet (body mass) index and effects of dapagliflozin in chronic kidney diseaseGlenn M Chertow, Priya Vart, Niels Jongs, et al.
The Lancet. Diabetes & Endocrinology|October 7, 2021
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialNiels Jongs, Tom Greene, Glenn M Chertow, et al.
Diabetes Care|June 29, 2021
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD TrialFrederik Persson, Peter Rossing, Priya Vart, et al.
European Heart Journal|April 1, 2021
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trialHiddo J L Heerspink, C David Sjöström, Niels Jongs, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2021
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trialDavid C Wheeler, Niels Jongs, Bergur V Stefansson, et al.
Diabetologia|April 21, 2022
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trialSimke W Waijer, Priya Vart, David Z I Cherney, et al.
Kidney International Reports|May 2, 2022
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic RegionsPriya Vart, Ricardo Correa-Rotter, Fan Fan Hou, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 8, 2020
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trialHiddo J L Heerspink, Bergur V Stefansson, Glenn M Chertow, et al.
Advances in Therapy|December 9, 2021
Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled TrialsJuan Jose Garcia Sanchez, Juliette Thompson, David A Scott, et al.
The Lancet. Diabetes & Endocrinology|October 7, 2021
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialHiddo J L Heerspink, Niels Jongs, Glenn M Chertow, et al.
Diabetes, Obesity & Metabolism|January 5, 2022
Quételet (body mass) index and effects of dapagliflozin in chronic kidney diseaseGlenn M Chertow, Priya Vart, Niels Jongs, et al.
The Lancet. Diabetes & Endocrinology|October 7, 2021
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialNiels Jongs, Tom Greene, Glenn M Chertow, et al.
Diabetes Care|June 29, 2021
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD TrialFrederik Persson, Peter Rossing, Priya Vart, et al.
European Heart Journal|April 1, 2021
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trialHiddo J L Heerspink, C David Sjöström, Niels Jongs, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2021
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trialDavid C Wheeler, Niels Jongs, Bergur V Stefansson, et al.
Diabetologia|April 21, 2022
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trialSimke W Waijer, Priya Vart, David Z I Cherney, et al.
Kidney International Reports|May 2, 2022
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic RegionsPriya Vart, Ricardo Correa-Rotter, Fan Fan Hou, et al.
Pageof 3